HC Wainwright Issues Pessimistic Forecast for Cognition Therapeutics (NASDAQ:CGTX) Stock Price

Cognition Therapeutics (NASDAQ:CGTX) had its target price decreased by HC Wainwright from $5.00 to $3.00 in a research report report published on Tuesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Other equities research analysts have also recently issued research reports about the stock. Chardan Capital dropped their price target on shares of Cognition Therapeutics from $8.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, May 8th. Brookline Capital Management raised shares of Cognition Therapeutics to a “strong-buy” rating in a report on Monday, January 27th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $5.63.

Cognition Therapeutics Stock Down 12.9%

Shares of Cognition Therapeutics stock opened at $0.26 on Tuesday. The firm has a market cap of $16.03 million, a PE ratio of -0.27 and a beta of 1.00. Cognition Therapeutics has a twelve month low of $0.25 and a twelve month high of $2.58. The business has a 50-day moving average price of $0.37 and a 200 day moving average price of $0.50.

Cognition Therapeutics (NASDAQ:CGTX) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). On average, sell-side analysts expect that Cognition Therapeutics will post -0.8 EPS for the current year.

Institutional Trading of Cognition Therapeutics

Institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new position in Cognition Therapeutics in the 4th quarter valued at $26,000. Northeast Financial Consultants Inc boosted its stake in Cognition Therapeutics by 158.6% during the 1st quarter. Northeast Financial Consultants Inc now owns 63,351 shares of the company’s stock worth $27,000 after purchasing an additional 38,851 shares during the last quarter. Two Sigma Investments LP raised its position in shares of Cognition Therapeutics by 372.2% in the fourth quarter. Two Sigma Investments LP now owns 53,691 shares of the company’s stock valued at $38,000 after buying an additional 42,321 shares during the last quarter. Virtu Financial LLC raised its position in shares of Cognition Therapeutics by 40.1% in the fourth quarter. Virtu Financial LLC now owns 80,180 shares of the company’s stock valued at $56,000 after buying an additional 22,949 shares during the last quarter. Finally, CM Management LLC lifted its stake in shares of Cognition Therapeutics by 100.0% in the first quarter. CM Management LLC now owns 400,000 shares of the company’s stock worth $168,000 after buying an additional 200,000 shares in the last quarter. 43.35% of the stock is owned by institutional investors and hedge funds.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.